Codes ATC:
H02AB02
EMLc
Indication
Lymphoid leukaemia, not elsewhere classified
Code ICD11:
2C03.3
INN
Dexamethasone
Type de médicament
Chemical agent
Type de liste
Liste complémentaire
(EML)
(EMLc)
(EMLc)
Formulations
Oral > Liquid:
2 mg per 5 mL
(EMLc)
Oral > Solid: 2 mg (EMLc) ; 4 mg
Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Solid: 2 mg (EMLc) ; 4 mg
Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
Sexe
Tous
Âge
Aussi recommandé pour les enfants
Équivalence thérapeutique
La recommandation concerne ce médicament spécifique
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite
sur les brevets.
Résumé des preuves et recommandation du comité d'experts
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for asparaginase on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia (ALL) was recommended. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ALL is attached.